Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants

Inclusion criteria: * Males or females between the ages of 18 and 65 suffering from seasonal allergic rhinitis provoked by ragweed pollen. * Having a 2-year history of seasonal allergic rhinitis with positive skin prick test to ragweed allergen at screening with a wheal diameter at least 3 mm larger than that produced by the negative control. * Subjects with antecedents of allergic seasonal allergic rhinitis symptom aggravation when exposed to pollen and air pollutants (i.e., cleaning products, diesel, paints). * Subjects having a total nasal symptom score ≥3 in Period 1 (Visit 2). Exclusion criteria: * History of anaphylaxis to ragweed pollen. * History of asthma. Mild asthmatics treated only with pro re nata short-acting beta2-agonists, 2 doses or less per week can be enrolled. * History of chronic sinusitis. * History of systemic disease affecting the immune system. * Evidence of any active or suspected bacterial, viral, fungal or parasitic infections within 30 days prior to allergen challenge. * Any history of Grade 4 anaphylaxis due to any cause as defined by the Common Terminology Criteria for Adverse Event grading criteria ("Life threatening consequences: urgent intervention indicated"). * Presence or history of drug hypersensitivity to fexofenadine. * Subjects receiving build-up injections of pollen allergen immunotherapy (those on stable maintenance dosing can be included). * Subjects taking any forbidden treatments/nutriments. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.